These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 19276552)

  • 1. Memantine and acetylcholinesterase inhibitor treatment in cases of CDR 0.5 or questionable impairment.
    McClendon MJ; Hernandez S; Smyth KA; Lerner AJ
    J Alzheimers Dis; 2009; 16(3):577-83. PubMed ID: 19276552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment of Alzheimer's disease: effect of race and demographic variables.
    Hernandez S; McClendon MJ; Zhou XH; Sachs M; Lerner AJ
    J Alzheimers Dis; 2010; 19(2):665-72. PubMed ID: 20110610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Retrospective Study on the Benefits of Combined Citicoline, Memantine, and Acetylcholinesterase Inhibitor Treatments in Older Patients Affected with Alzheimer's Disease.
    Castagna A; Fabbo A; Manzo C; Lacava R; Ruberto C; Ruotolo G
    J Alzheimers Dis; 2021; 79(4):1509-1515. PubMed ID: 33459645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
    Gareri P; Putignano D; Castagna A; Cotroneo AM; De Palo G; Fabbo A; Forgione L; Giacummo A; Lacava R; Marino S; Simone M; Zurlo A; Putignano S
    J Alzheimers Dis; 2014; 41(2):633-40. PubMed ID: 24643135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial and Ethnic Differences in Initiation and Discontinuation of Antidementia Drugs by Medicare Beneficiaries.
    Thorpe CT; Fowler NR; Harrigan K; Zhao X; Kang Y; Hanlon JT; Gellad WF; Schleiden LJ; Thorpe JM
    J Am Geriatr Soc; 2016 Sep; 64(9):1806-14. PubMed ID: 27549029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.
    Calvó-Perxas L; Turró-Garriga O; Vilalta-Franch J; Lozano-Gallego M; de Eugenio R; Márquez F; Carmona O; Gich J; Manzano A; Viñas M; Roig AM; Garre-Olmo J;
    Drugs Aging; 2017 Apr; 34(4):303-310. PubMed ID: 28258538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Racial/ethnic disparities in initiation and persistent use of anti-dementia medications.
    Zhu CW; Neugroschl J; Barnes LL; Sano M
    Alzheimers Dement; 2022 Dec; 18(12):2582-2592. PubMed ID: 35218291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
    Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
    J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy Is Good Enough for Patients with Mild-to-Moderate Alzheimer's Disease: A Network Meta-analysis of 76 Randomized Controlled Trials.
    Tsoi KK; Chan JY; Chan FC; Hirai HW; Kwok TC; Wong SY
    Clin Pharmacol Ther; 2019 Jan; 105(1):121-130. PubMed ID: 29717478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia.
    Knight R; Khondoker M; Magill N; Stewart R; Landau S
    Dement Geriatr Cogn Disord; 2018; 45(3-4):131-151. PubMed ID: 29734182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Antidementia Therapies With Time to Skilled Nursing Facility Admission and Cardiovascular Events Among Elderly Adults With Alzheimer Disease.
    San-Juan-Rodriguez A; Zhang Y; He M; Hernandez I
    JAMA Netw Open; 2019 Mar; 2(3):e190213. PubMed ID: 30821828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease.
    Lampela P; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H
    J Alzheimers Dis; 2020; 73(3):1243-1251. PubMed ID: 31929157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.
    Schneider LS; Insel PS; Weiner MW;
    Arch Neurol; 2011 Jan; 68(1):58-66. PubMed ID: 21220675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations.
    Gilligan AM; Malone DC; Warholak TL; Armstrong EP
    Am J Geriatr Pharmacother; 2012 Oct; 10(5):303-12. PubMed ID: 23063286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-label medication use in frontotemporal dementia.
    Bei Hu ; Ross L; Neuhaus J; Knopman D; Kramer J; Boeve B; Caselli RJ; Graff-Radford N; Mendez MF; Miller BL; Boxer AL
    Am J Alzheimers Dis Other Demen; 2010 Mar; 25(2):128-33. PubMed ID: 20124256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia].
    Portela Romero M; Pombo Romero J; Bugarín González R; Tasende Souto M; Represa Veiga S
    Rev Esp Salud Publica; 2005; 79(6):665-72. PubMed ID: 16457058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
    Taipale H; Tanskanen A; Koponen M; Tolppanen AM; Tiihonen J; Hartikainen S
    Int Clin Psychopharmacol; 2014 Jul; 29(4):216-23. PubMed ID: 24608822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.
    Parsons CG; Danysz W; Dekundy A; Pulte I
    Neurotox Res; 2013 Oct; 24(3):358-69. PubMed ID: 23657927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.